20.09.2023 Mainz BioMed N.V.  NL0015000LC2

EQS-News: Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference


 

Issuer: Mainz BioMed N.V. / Key word(s): Conference
Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference

20.09.2023 / 09:01 CET/CEST
The issuer is solely responsible for the content of this announcement.


 Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference 

BERKELEY, US – MAINZ, Germany – September 20, 2023Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Guido Baechler, Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference which takes place September 26-28, 2023 in New York City.

This year’s conference is expected to bring together key opinion leaders from public and private companies for in-depth discussions on the developments and trends shaping diagnostics and other healthcare-related industry sectors.

Mr. Baechler’s presentation will take place on September 28th at 10.20am ET and will be available to watch via video webcast both live, and on replay for 90 days post event, by following this access link. He will be available for 1-on-1 meetings with investors after the presentation and throughout the day (28th).

For more information on the Global Healthcare Conference, please visit https://www.cantor.com/our-company/conferences/global-healthcare-conference-2023/.

About Mainz Biomed NV  
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert® is currently marketed across Europe. The Company is running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter/X and Facebook.   

For media inquiries - [email protected] 

In Europe:
MC Services AG
Anne Hennecke/Caroline Bergmann
+49 211 529252 20
[email protected]

In the U.S.:
Josh Stanbury
+1 416 628 7441
[email protected]

For investor inquiries, please contact [email protected]

Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 7, 2023. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.



Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Mainz BioMed N.V.
Robert-Koch-Strasse 50
55129 Mainz
Germany
Internet: mainzbiomed.com
EQS News ID: 1728899

 
End of News EQS News Service

fncls.ssp?fn=show_t_gif&application_id=1728899&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023
Umsatzerlöse1 0,00 0,00 0,25 0,40 0,51 0,50 0,81
EBITDA1,2 0,00 0,00 -0,78 -0,50 -8,52 -24,47 -23,35
EBITDA-Marge3 0,00 0,00 -312,00 -125,00 -1.670,59 -4.894,00
EBIT1,4 0,00 0,00 -0,82 -0,55 -8,59 -24,83 -24,14
EBIT-Marge5 0,00 0,00 -328,00 -137,50 -1.684,31 -4.966,00 -2.980,25
Jahresüberschuss1 0,00 0,00 -0,85 -0,48 -10,32 -24,71 -23,82
Netto-Marge6 0,00 0,00 -340,00 -120,00 -2.023,53 -4.942,00 -2.940,74
Cashflow1,7 0,00 0,00 -0,37 -0,38 -2,84 -13,83 -19,88
Ergebnis je Aktie8 0,00 0,00 -0,15 -0,08 -1,43 -1,74 -1,47
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Reliant CPA

INVESTOR-INFORMATIONEN
©boersengefluester.de
Mainz Biomed
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A3C6XX 0,350 Halten 7,66
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 -0,24
KBV KCV KUV EV/EBITDA
2,60 - 9,43 -0,29
Dividende '22 in € Dividende '23 in € Div.-Rendite '23
in %
Hauptversammlung
0,00 0,00 0,00 31.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
24.04.2024 02.07.2024 16.11.2023 09.04.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-35,92% -65,08% -65,55% -91,36%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Mainz BioMed N.V.  ISIN: NL0015000LC2 können Sie bei EQS abrufen


Biotechnologie , A3C6XX , 4TO , FWB:4TO